AARD (Aardvark Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AARD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-21 | Jeffrey Chi | Director | A | — | — |
| 2026-08-21 | Roy D. Baynes | Director | A | — | — |
| 2026-08-21 | Susan E Graf | Director | A | — | — |
| 2026-08-21 | Victor Edward Tong Jr | Director | A | — | — |
| 2026-02-11 | Tien-Li Lee | Chief Executive Officer | A | — | — |
| 2026-02-11 | Manasi Jaiman | Chief Medical Officer | A | — | — |
| 2026-02-11 | Nelson Sun | Chief Financial Officer | A | — | — |
| 2025-12-12 | Tien-Li Lee | Chief Executive Officer | Buy | — | — |
| 2025-12-12 | Nelson Sun | Chief Financial Officer | Buy | — | — |
| 2025-10-16 | Bryan Jones | Chief Operating Officer | M | — | — |
| 2025-10-16 | Tien-Li Lee | Chief Executive Officer | M | — | — |
| 2025-09-16 | Tien-Li Lee | Chief Executive Officer | Buy | — | — |
| 2025-09-12 | Tien-Li Lee | Chief Executive Officer | Buy | — | — |
| 2025-09-10 | Nelson Sun | Chief Financial Officer | Buy | — | — |
| 2025-08-29 | Tien-Li Lee | Chief Executive Officer | M | — | — |
| 2025-06-13 | Susan E Graf | Director | A | — | — |
| 2025-06-13 | Roy D. Baynes | Director | A | — | — |
| 2025-06-13 | Victor Edward Tong Jr | Director | A | — | — |
| 2025-06-13 | Bryan Jones | Chief Operating Officer | A | — | — |
| 2025-06-13 | Nelson Sun | Chief Financial Officer | A | — | — |
| 2025-06-13 | Tien-Li Lee | Chief Executive Officer | A | — | — |
| 2025-06-13 | Manasi Jaiman | Chief Medical Officer | A | — | — |
| 2025-06-13 | Jeffrey Chi | Director | A | — | — |
| 2025-02-19 | Bihua Chen | — | MIXED | — | — |
| 2025-02-19 | Tien-Li Lee | Chief Executive Officer | MIXED | — | — |
| 2025-02-19 | Nelson Sun | Chief Financial Officer | MIXED | — | — |
| 2025-02-19 | Jeffrey Chi | Director | C | — | — |
| 2025-02-19 | Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | MIXED | — | — |
| 2025-02-19 | Vickers Venture Fund VI Pte Ltd | 10%+ Owner | C | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 3,025,641 | — |
| — | 10%+ Owner | 2,333,887 | — |
| — | 10%+ Owner | 2,050,902 | — |
| — | — | 800,189 | — |
| — | Director | 133,364 | — |
| — | Chief Financial Officer | 108,484 | — |
| — | Chief Operating Officer | 1,250 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AARD quote page; the site-wide leaderboard is on the insider transactions hub.